vs
Side-by-side financial comparison of American Express (AXP) and HARVARD BIOSCIENCE INC (HBIO). Click either name above to swap in a different company.
American Express is the larger business by last-quarter revenue ($18.9B vs $23.7M, roughly 796.6× HARVARD BIOSCIENCE INC). American Express runs the higher net margin — 15.7% vs -12.0%, a 27.7% gap on every dollar of revenue. On growth, American Express posted the faster year-over-year revenue change (11.4% vs -3.3%). Over the past eight quarters, American Express's revenue compounded faster (38.8% CAGR vs -1.6%).
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...
Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.
AXP vs HBIO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.9B | $23.7M |
| Net Profit | $3.0B | $-2.8M |
| Gross Margin | — | 59.7% |
| Operating Margin | — | 7.2% |
| Net Margin | 15.7% | -12.0% |
| Revenue YoY | 11.4% | -3.3% |
| Net Profit YoY | 15.0% | -15916.7% |
| EPS (diluted) | $4.28 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.9B | — | ||
| Q4 25 | $10.9B | $23.7M | ||
| Q3 25 | $10.4B | $20.6M | ||
| Q2 25 | $10.3B | $20.4M | ||
| Q1 25 | $9.6B | $21.8M | ||
| Q4 24 | $10.0B | $24.6M | ||
| Q3 24 | $9.7B | $22.0M | ||
| Q2 24 | $9.8B | $23.1M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $2.5B | $-2.8M | ||
| Q3 25 | $2.9B | $-1.2M | ||
| Q2 25 | $2.9B | $-2.3M | ||
| Q1 25 | $2.6B | $-50.3M | ||
| Q4 24 | $2.2B | $18.0K | ||
| Q3 24 | $2.5B | $-4.8M | ||
| Q2 24 | $3.0B | $-2.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 58.4% | ||
| Q2 25 | — | 56.4% | ||
| Q1 25 | — | 56.0% | ||
| Q4 24 | — | 57.1% | ||
| Q3 24 | — | 58.1% | ||
| Q2 24 | — | 57.2% |
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | 7.2% | ||
| Q3 25 | 36.7% | 1.0% | ||
| Q2 25 | 34.4% | -4.0% | ||
| Q1 25 | 34.6% | -228.1% | ||
| Q4 24 | 27.7% | 0.0% | ||
| Q3 24 | 33.0% | -8.5% | ||
| Q2 24 | 38.6% | -9.0% |
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | -12.0% | ||
| Q3 25 | 27.9% | -6.0% | ||
| Q2 25 | 28.0% | -11.2% | ||
| Q1 25 | 26.8% | -231.2% | ||
| Q4 24 | 21.8% | 0.1% | ||
| Q3 24 | 25.8% | -21.9% | ||
| Q2 24 | 30.7% | -12.7% |
| Q1 26 | $4.28 | — | ||
| Q4 25 | $3.52 | $-0.06 | ||
| Q3 25 | $4.14 | $-0.03 | ||
| Q2 25 | $4.08 | $-0.05 | ||
| Q1 25 | $3.64 | $-1.14 | ||
| Q4 24 | $3.04 | $0.01 | ||
| Q3 24 | $3.49 | $-0.11 | ||
| Q2 24 | $4.15 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $8.6M |
| Total DebtLower is stronger | $60.4M | $35.9M |
| Stockholders' EquityBook value | $34.0M | $13.7M |
| Total Assets | $308.9M | $80.1M |
| Debt / EquityLower = less leverage | 1.78× | 2.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | $8.6M | ||
| Q3 25 | $1.3B | $6.8M | ||
| Q2 25 | $197.0M | $7.4M | ||
| Q1 25 | $261.0M | $5.5M | ||
| Q4 24 | $221.0M | $4.1M | ||
| Q3 24 | $120.0M | $4.6M | ||
| Q2 24 | $188.0M | $4.0M |
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | $35.9M | ||
| Q3 25 | $57.8B | $34.0M | ||
| Q2 25 | $58.2B | $34.9M | ||
| Q1 25 | $51.2B | $36.4M | ||
| Q4 24 | $49.7B | $37.0M | ||
| Q3 24 | $53.5B | $34.9M | ||
| Q2 24 | $51.5B | $35.7M |
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | $13.7M | ||
| Q3 25 | $32.4B | $14.1M | ||
| Q2 25 | $32.3B | $15.7M | ||
| Q1 25 | $31.2B | $14.8M | ||
| Q4 24 | $30.3B | $63.3M | ||
| Q3 24 | $29.7B | $65.3M | ||
| Q2 24 | $29.5B | $67.2M |
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | $80.1M | ||
| Q3 25 | $297.6B | $78.0M | ||
| Q2 25 | $295.6B | $80.1M | ||
| Q1 25 | $282.2B | $79.8M | ||
| Q4 24 | $271.5B | $126.6M | ||
| Q3 24 | $271.0B | $131.2M | ||
| Q2 24 | $272.2B | $128.9M |
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | 2.61× | ||
| Q3 25 | 1.78× | 2.41× | ||
| Q2 25 | 1.80× | 2.22× | ||
| Q1 25 | 1.64× | 2.45× | ||
| Q4 24 | 1.64× | 0.58× | ||
| Q3 24 | 1.80× | 0.53× | ||
| Q2 24 | 1.74× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-96.0K |
| Free Cash FlowOCF − Capex | — | $-545.0K |
| FCF MarginFCF / Revenue | — | -2.3% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $-96.0K | ||
| Q3 25 | $6.2B | $1.1M | ||
| Q2 25 | $4.4B | $2.8M | ||
| Q1 25 | $4.8B | $3.0M | ||
| Q4 24 | $5.8B | $1.7M | ||
| Q3 24 | $-1.8B | $-842.0K | ||
| Q2 24 | $4.5B | $-846.0K |
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | $-545.0K | ||
| Q3 25 | $5.6B | $877.0K | ||
| Q2 25 | $3.7B | $2.7M | ||
| Q1 25 | $4.3B | $2.5M | ||
| Q4 24 | $5.3B | $1.4M | ||
| Q3 24 | $-2.3B | $-1.7M | ||
| Q2 24 | $4.0B | $-1.7M |
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | -2.3% | ||
| Q3 25 | 53.6% | 4.3% | ||
| Q2 25 | 36.3% | 13.0% | ||
| Q1 25 | 45.0% | 11.4% | ||
| Q4 24 | 53.1% | 5.8% | ||
| Q3 24 | -23.3% | -7.8% | ||
| Q2 24 | 40.4% | -7.2% |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 1.9% | ||
| Q3 25 | 6.3% | 1.0% | ||
| Q2 25 | 6.0% | 0.4% | ||
| Q1 25 | 4.5% | 2.4% | ||
| Q4 24 | 5.0% | 1.2% | ||
| Q3 24 | 4.7% | 4.0% | ||
| Q2 24 | 5.8% | 3.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | — | ||
| Q3 25 | 2.15× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 1.84× | — | ||
| Q4 24 | 2.66× | 95.83× | ||
| Q3 24 | -0.72× | — | ||
| Q2 24 | 1.50× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXP
Segment breakdown not available.
HBIO
| Instruments Equipment Software And Accessories | $21.6M | 91% |
| Service Maintenance And Warranty Contracts | $2.1M | 9% |
